Skip to main content

About your Search

Search Results 0 to 0 of about 1
of money to develop them. but then again, we all have this problem with keeping health care costs down and obama care wants generic competition for biologics. what's the right road to take there? >> you know, joe, we've been in this industry for over 135 years. for us, we've taken a focus and we pursue both small molecule as well as bioological routes to address some of the most oppressing diseases out there. if you take alzheimer's, we have the biologic but we have a base inhibitor in phase two -- >> would you pay a lobbyist, would you get lobbyists for eli lilly to try to make it that you don't have to have generic competition for biologics, is that something eli lilly would do, or do you go along with it? >> well, remember, in the affordable care act we did get an extension in terms of data protection, as we should be, to at least 12 years. we believe that's very important for us to have a reasonable period to generate return on investment that we make in r&d. we still are the industry that invests the most in r&d, research and development, in this country. we from a policy standpoi
Search Results 0 to 0 of about 1